35 years of kids’ health research,
THE KIDS RESEARCH INSTITUTE AUSTRALIA
With
Professor Jonathan Carapetis AM,
Paediatrician & Executive Director
The Kids Research Institute Australia
RESEARCH IMPACT
Filmed in Perth, Western Australia | January 2026
The Kids Research Institute Australia is one of the largest and most successful medical research institutes in Australia. The Institute has created a blueprint that brings together community, researchers, practitioners, policy makers and funders, who share our vision to improve the health and wellbeing of children through excellence in research.
The Institute is headed by leading paediatrician and infectious diseases expert Professor Jonathan Carapetis, with Founding Director Professor Fiona Stanley now Patron.
The Kids is independent and not-for-profit. The majority of funding comes from our success in winning national and international competitive research grants. They also receive significant philanthropic support from corporate Australia and the community.
In November 2025, The Kids Research Institute Australia celebrated 35 years of bold ideas, groundbreaking research, and the people who find answers to the big questions about better health outcomes for children and families.
Since his appointment in 2012, Professor Carapetis has guided The Kids through a period of significant scientific achievement, organisational growth, and increased impact — all anchored to the Institute’s vision of ensuring happy, healthy kids.
During his tenure, Professor Carapetis oversaw major advancements in child health research, including discoveries that have influenced policy and practice, such as the recent adoption of RSV vaccinations.
He led the Institute through key milestones including the transition to new headquarters at Perth Children’s Hospital, the development of the Research Reimagined strategic plan, and the creation of a new, fresh brand.
Under Professor Carapetis’ leadership, The Kids strengthened its position as a national leader in child health research, building collaborations across Australia and internationally, supporting researchers and WA families through the COVID-19 pandemic, and driving a culture that has evolved traditional models of research, to accelerate and amplify impact, for children and their families.
Also announced in November 2025, was the news that Professor Carapetis will step down as Executive Director in July 2026, after 14 years of distinguished leadership.
Source: Adapted using The Kids Research Institute Australia news stories
-
CASE STUDY Next Generation Condom Contraception
Eudaemon Technologies, an early-stage medtech company with a focus on sexual reproductive health, is developing a hydrogel condom to address the need for a better feeling, next generation condom, with the potential to improve user experience and address issues with traditional latex condoms.
“Over 1 million STI’s being diagnosed every day and up to 120 million unplanned pregnancies every year result in a $60 billion health burden across the globe”, says Co-Founder and Executive Director of Operations, Dr Simon Cook.
Formed in 2018, the company focuses on developing tough hydrogels as an alternative to address issues with odour, colour, and taste commonly associated with latex condoms. This technology can be loaded with small molecule drugs for flavours or anti-STI compounds, and was developed in response to a grant from the Bill and Melinda Gates Foundation to address unplanned pregnancies and STIs.
-
Lasers, microbiology and dental materials in clinical dental practice
Professor Laurence Walsh AO is an Emeritus Professor at the University of Queensland, holding an adjunct title at Griffith University and a part-time position as the Chief Dental Officer at Dentroid, which is based in Canberra. In addition to these roles, he serves on several committees of the Dental Association and is the current president of the Australian Society for Laser Dentistry.
-
Respiratory health and the microbiome in the lung environment
Dr Taylor leads the Respiratory Health Group within the Microbiome and Host Health Program. His research employs tailored techniques that allow the lung environment to be characterised to a high level of accuracy, including detailed measurements of airway microbiology (microbiome), mucus composition, and inflammation. This information is used to identify predictive markers of chronic lung disease severity as well as determine effective forms of therapy.
